MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3

MoonLake Immunotherapeutics

2024-FY EPS reported -$1.89

Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.
R&D expenses rose to $112.8M in 2024 from $31.8M in 2023 as Phase 3 trials for HS and PsA started.
Cash and equivalents of $448.0M as of Dec 31, 2024, down from $493.9M in Q3 2024; runway to end of 2026.
Initiated Phase 3 VELA (HS), Phase 3 IZAR (PsA), plus Phase 2 trials in PPP, axSpA, and adolescent HS.
Capital Markets Update planned for Q2 2025 to discuss Phase 3 HS data and financials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.